NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" [...]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" [...]
Lipum AB (publ) ("Lipum" or the "Company") announces that the subscription period in the Company’s capital raising begins today and runs until July 18, 2023. Lipum wants to inform that Erik Penser Bank has published a company presentation and an interview with the Company's CEO, Einar Pontén. The purpose of the company presentation and interview [...]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" [...]
An Extraordinay General Meeting (the ”EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”) today resolved to approve the Board of Directors’ resolution on a rights issue of up to 2,870,334 new shares. On 8 June 2023, the Board of Directors resolved, subject to approval by an EGM, on a rights [...]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" [...]
Do not miss Lipum's presentation at the BioStock Life Science Spring Summit, today May 31 at 10.40. The event starts at 10.00 - see the full programme on BioStock's website (https://www.biostock.se/en/biostock-life-science-summit-may-2023/) or YouTube channel (https://www.youtube.com/channel/UCHXuEgaQtQHZtLCvCJqkT-Q). CEO Einar Ponténwill present Lipum at the BioStock Life Science Spring Summit (https://www.biostock.se/en/biostock-life-science-summit-may-2023/), starting at 10.40. This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/
Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “I am excited about our ongoing Phase 1 clinical trial of the drug candidate SOL-116 as everything is going according [...]
Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “In the fourth quarter, we started a first in man phase 1 clinical trial of our drug candidate SOL-116, achieving the major [...]
Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety evaluation has now been conducted and as expected, data show that SOL-116 remains safe and well tolerated. The study is therefore continuing as planned with a higher dose level [...]